Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004... by van Rossum, A.G.J., Kok, M., van Werkhoven, E., Opdam, M., Mandjes, I.A.M., van Leeuwen – Stok, A.E., van Tinteren, H., Imholz, A.L.T., Portielje, J.E.A., Bos, M.M.E.M., van Bochove, A., Wesseling, J., Rutgers, E.J., Linn, S.C., Oosterkamp, H.M.

Get full text

The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measure by Jebbink, M., van Werkhoven, E., Mandjes, I. A. M., Wesseling, J., Lips, E. H., Vrancken Peeters, M.-J. T. D. F., Loo, C. E., Sonke, G. S., Linn, S. C., Falo Zamora, C., Rodenhuis, S.

Get full text

Abstract OT2-07-08: Substantially improving the cure rate of high-risk BRCA1-like breast cancer patients with personalized therapy (SUBITO) - an international randomized phase III... by Vliek, S, Jager, A, Jonge-Lavrencic, M, Lotz, J-P, Gonçalves, A, Graeser, M, Nitz, U, Mandjes, IAM, Holtkamp, MJ, Schot, M, Retel, VP, Kuip, EJ, Wymenga, MN, Konings, IR, Tjan-Heijnen, VCG, Kroep, JR, Schroeder, CP, Van der Wall, E, Linn, SC

Get full text

Abstract P1-14-16: Weekly paclitaxel, trastuzumab, carboplatin is a highly effective neoadjuvant regimen in HER2-positive breast cancer: Results from the TRAIN-study by van Ramshorst, MS, van Werkhoven, E, Mandjes, IAM, Schot, M, Wesseling, J, Vrancken Peeters, M-JTFD, Rodenhuis, S, Oosterkamp, HM, Bos, MEM, Meerum Terwogt, JM, Linn, SC, Sonke, GS

Get full text

Abstract OT2-01-11: Phase II of POSEIDON: A phase Ib / randomized phase II trial of tamoxifen plus taselisib or placebo in hormone receptor positive, HER2 negative, metastatic brea... by Oliveira, M, Baird, RD, van Rossum, AGJ, Beelen, K, Garcia-Corbacho, J, Mandjes, IAM, Vallier, AL, van Werkhoven, E, Garrigós, L, Kumar, S, van Tinteren, H, Muñoz, S, Linossi, C, Rosing, H, Miquel, JM, Schrier, M, de Vries Schultink, A, Saura, C, Gallagher, WM, Bernards, R, Tabernero, J, Cortés, J, Caldas, C, Linn, SC

Get full text

Abstract P5-14-03: Adjuvant dose dense doxorubicin-cyclophosphamide (ddAC) or docetaxel-AC (TAC) for high-risk breast cancer: First results of the randomized MATADOR trial (BOOG-20... by van Rossum, AGH, Oosterkamp, HM, van Werkhoven, E, Opdam, M, Mandjes, IAM, van Leeuwen-Stok, E, van Tinteren, H, Kok, M, Imholz, ALT, Portielje, JEA, Bos, MMEM, van Bochove, A, Wesseling, J, Rutgers, EJ, Rodenhuis, S, Linn, SC

Get full text

Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer by Terwogt, J M M, Mandjes, I A M, Sindermann, H, Beijnen, J H, ten Bokkel Huinink, W W

Get full text

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide by Herben, VMM, ten Bokkel Huinink, WW, Dubbelman, AC, Mandjes, IAM, Groot, Y, van Gortel-van Zomeren, DM, Beijnen, JH

Get full text